BeStock  
Stocks › Biotechnology › LGND

Ligand Pharmaceuticals LGND

US equityMarket cap rank #1897Biotechnology
$286.85 −$0.09 (-0.03%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $286.85 0.00%
Open$285.21
Prev close$286.94
Day range$282.36 – $291.36
Volume259.8K
Market cap$5.74B
P/E (TTM)115.2
Dividend yield–

Earnings

Average move on report day±5.8%last 16 reports
Closed higher11 of 1669% of the time
Best reaction+19.9%
Worst reaction-9.6%

Stock move on the day after each report

+19.9%2023/Q4+9.8%2024/Q1-5.8%2024/Q2+11.1%2024/Q3+0.6%2024/Q4-2.9%2025/Q1+2.8%2025/Q2+9.4%2025/Q3+2.5%2025/Q4-9.6%2026/Q1-0.8%2026/Q2-0.5%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q329 Oct 2026Pre Market±7.5%-0.45%Within range
2026/Q26 Aug 2026Pre Market±7.0%-0.80%Within range
2026/Q17 May 2026Pre Market±6.3%-9.55%Bigger than priced
2025/Q426 Feb 2026Pre Market±8.1%+2.50%Within range
2025/Q36 Nov 2025Pre Market±5.7%+9.37%Bigger than priced
2025/Q27 Aug 2025Pre Market±7.2%+2.75%Within range
2025/Q18 May 2025Pre Market±11.7%-2.94%Within range
2024/Q427 Feb 2025Pre Market±10.2%+0.57%Within range
2024/Q37 Nov 2024Pre Market±9.2%+11.12%Bigger than priced
2024/Q26 Aug 2024After Market±9.5%-5.78%Within range
2024/Q17 May 2024After Market±9.6%+9.75%Bigger than priced
2023/Q427 Feb 2024Pre Market±8.2%+19.86%Bigger than priced
2023/Q38 Nov 2023After Market±12.0%+4.61%Within range
2023/Q28 Aug 2023After Market±8.1%+5.35%Within range
2023/Q14 May 2023After Market±11.5%+3.42%Within range
2022/Q422 Feb 2023After Market±13.8%+4.12%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Latest reported quarter: Q3, ended Sep 2026

Revenue$78.75M-31.8% YoY
Operating profit-$9.49M-117.5% YoY
Net profit-$28.49M-124.3% YoY
Diluted EPS-$1.43-125.2% YoY
Free cash flow-$57.60M-1,329.7% YoY
Operating cash flow-$27.59M

Revenue, last 8 quarters

$42.8MDec '24$45.3MMar '25$47.6MJun '25$115.5MSep '25$59.7MDec '25$51.7MMar '26$63.7MJun '26$78.7MSep '26

Net profit, last 8 quarters

$-31.1MDec '24$-42.5MMar '25$4.8MJun '25$117.3MSep '25$44.8MDec '25$-13.3MMar '26$48.5MJun '26$-28.5MSep '26

Profitability & balance sheet

Gross margin95.2%
Operating margin14.4%
Net margin20.3%
Return on equity5.4%
Return on assets2.8%
Return on invested capital1.9%
Current ratio1.22
Liabilities / assets57.0%
Cash & investments$474.89M
Total debt$1.15B
Net cash (debt)-$674.76M
Free cash flow / sales22.6%

Discussion

No comments yet — be the first to weigh in on LGND.

Sign in to join the discussion.

Scroll to Top